Royal London Asset Management
MRNA icon

Royal London Asset Management’s Moderna MRNA Stock Holding History

Royal London Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-144,232
Closed -$3.98M – 711
2025
Q2 		$3.98M Sell
144,232
-16,035
-10% -$422K 0.01% 566
2025
Q1 		$4.54M Sell
160,267
-361
-0.2% -$12.8K 0.01% 569
2024
Q4 		$6.68M Sell
160,628
-178,991
-53% -$8.55M 0.02% 506
2024
Q3 		$22.7M Buy
339,619
+4,310
+1% +$396K 0.06% 274
2024
Q2 		$39.8M Sell
335,309
-51,219
-13% -$6.48M 0.1% 167
2024
Q1 		$41.2M Buy
386,528
+18,913
+5% +$1.91M 0.1% 167
2023
Q4 		$36.6M Buy
367,615
+8,542
+2% +$718K 0.1% 169
2023
Q3 		$37.1M Sell
359,073
-32,146
-8% -$3.59M 0.12% 144
2023
Q2 		$47.5M Sell
391,219
-18,971
-5% -$2.53M 0.15% 120
2023
Q1 		$63M Buy
410,190
+147,774
+56% +$24.4M 0.25% 79
2022
Q4 		$47.1M Buy
262,416
+64,352
+32% +$10.5M 0.21% 95
2022
Q3 		$23.4M Buy
198,064
+21,337
+12% +$3.24M 0.12% 156
2022
Q2 		$25.2M Buy
176,727
+692
+0.4% +$98.9K 0.12% 159
2022
Q1 		$30.3M Buy
176,035
+5,699
+3% +$959K 0.12% 156
2021
Q4 		$43.3M Buy
170,336
+50,701
+42% +$14.8M 0.16% 119
2021
Q3 		$46.1M Sell
119,635
-2,099
-2% -$774K 0.19% 106
2021
Q2 		$28.6M Buy
121,734
+15,022
+14% +$2.68M 0.12% 157
2021
Q1 		$14M Buy
106,712
+2,557
+2% +$371K 0.06% 249
2020
Q4 		$10.9M Sell
104,155
-3,099
-3% -$314K 0.06% 274
2020
Q3 		$7.56M Buy
+107,254
New +$7.48M 0.05% 307

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Royal London Asset Management's MRNA Position: Q3 2025 in Review

Royal London Asset Management sold out of Moderna (MRNA) in Q3 2025, closing a stake of 144,232 shares — an estimated $3.98M sold.

Royal London Asset Management first reported a position in MRNA in Q3 2020 and held it in 20 quarters. The position peaked at $63M in Q1 2023. 644 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Royal London Asset Management reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Royal London Asset Management sold 144,232 Moderna shares in Q3 2025, an estimated $3.98M.
  • Royal London Asset Management first reported a position in Moderna in Q3 2020 and held it in 20 quarters.
  • Royal London Asset Management's Moderna position peaked at $63M in Q1 2023.
  • 644 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Royal London Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.